INTRODUCTION
============

Inflammatory bowel disease (IBD), which includes Crohn\'s disease (CD) and ulcerative colitis (UC), is characterized by chronic relapsing inflammation of the gastrointestinal tract. Azathioprine (AZA) is the most common drug used to maintain clinical remission in CD and UC.[@B1],[@B2] This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active IBD. However, the dose of AZA has to be reduced or the therapy has to be discontinued in 9-28% of patients because of drug-induced toxicity.[@B3] Bone marrow suppression, gastrointestinal disturbances, hepatotoxicity, pancreatitis, fever, and rash are among the most frequent reasons for AZA reduction/cessation in some patients.[@B4] Although there are some adverse reactions that clinicians should be aware of, monitoring 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) levels enables safe and long-term remission in IBD patients.[@B5],[@B6]

Thiopurine S-methyltransferase (TPMT) is the key enzyme in the metabolic pathway of thiopurine compounds. Patients with low enzyme activity have elevated 6-TGN levels and an increased risk of bone marrow suppression when treated with standard doses of AZA.[@B7],[@B8] Patients with high enzyme activity are either resistant to AZA due to shunting of thiopurine drugs down the 6-MMP pathway[@B9],[@B10],[@B11] or require a high dose to achieve efficacy, but have an increased risk of hepatotoxicity due to high 6-MMP levels.[@B12],[@B13] About 10% of the patients are intermediate activity group due to heterozygosity of the TPMT, and 0.3% of the patients have undetectable TPMT activity as an homozygote.[@B9] The wild type is TPMT\*1, and TPMT\*3A is the most common mutant allele (85%) in Caucasians[@B9] and TPMT\*3C is the most prevalent mutant allele in Africans and Asians.[@B12],[@B13],[@B14]

The aim of this study was to evaluate the role of 6-TGN and TPMT as predictors of adverse effects and clinical resp-onse to AZA, using a well-powered study of pediatric patients with IBD. We also tried to determine the optimal dose of AZA maintaining remission in the Korean pediatric IBD patients.

MATERIALS AND METHODS
=====================

Patients
--------

Among pediatric patients who were diagnosed with CD or UC in accordance with the European Society for Pediatric Gastroenterology, Hepatology and Nutrition-Porto criteria[@B15] at the Samsung Medical Center from March 2004 to October 2011, we enrolled 109 patients who required AZA to maintain remission. There were 87 CD patients and 22 UC patients ranging in age from 3 to 21 years. Before using AZA, the TPMT genotype was analyzed. The patients had been prescribed a consistent dose of AZA for at least 3 months prior to the study. A retrospective chart analysis was conducted by physician notes, laboratory studies, radiology reports, endoscopy records, and histology reports. This study was approved by our Institutional Review Board.

Analysis of TPMT genotype was available throughout the study period, and thiopurine metabolite monitoring has been available since September 2010. One hundred and nine IBD patients have been monitored for thiopurine metabolites since September 2010. Of them, 83 cohorts who had received a consistent dose of AZA for at least 3 months prior to September 2010 were selected and followed until October 2011 for the assessment of adverse drug reactions (ADR), disease activity and optimal AZA dose to maintain remission at pre- and post-thiopurine metabolite monitoring period. The appraisal of ADR, disease activity and AZA dose in 83 patients was performed and compared between just before the beginning of thiopurine metabolite monitoring (September 2010) and when 6-TGN level attained an optimal therapeutic range of approximately 235-450 pmol/8×10^8^ red blood cells (RBC).[@B16],[@B17]

AZA treatment was initiated at a dose of approximately 1.0 mg/kg per day and then increased to approximately 1.5 mg/kg per day in order to maintain remission during maintenance therapy. Patients were required to visit the outpatient clinic at least once a month before remission of the disease, and once every 2 to 3 months after remission was obtained. Laboratory tests were conducted in order to monitor disease activity and adverse drug reactions at each visit. Routine blood examinations including complete blood cell counts, erythrocyte sedimentation rate, albumin, transaminase, amylase, lipase and C-reactive protein were carried out. Disease activity was evaluated using the pediatric UC activity index (PUCAI)[@B18] and the pediatric CD activity index (PCDAI).[@B19] In both activity indices, scores of less than 10 points are considered to be in remission, while scores above 10 points are considered indicative of active disease.

Analysis of the TPMT genotype
-----------------------------

Whole blood specimens were collected into EDTA tubes, and genomic DNA was isolated from peripheral blood leukocytes using the Wizard Genomic DNA Purification kit according to the manufacturer\'s instructions (Promega, Madison, WI, USA).

All nine exons of the TPMT gene were amplified on a model 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) using oligonucleotide primers and conditions as previously described with some modifications.[@B20],[@B21] Direct sequencing was performed using ABI Big Dye Terminator kit v1.1 (Applied Biosystems) according to the manufacturer\'s instructions. To identify sequence variations, patient sequences were compared with respective reference sequences using the Sequencher software (Gene Codes Corporation, Ann Arbor, MI, USA).

6-TGN and 6-MMP assay
---------------------

Measurements of the RBC 6-TGN and 6-MMP levels were performed on the Waters 2795 Alliance high-performance liquid chromatography system and a Quatro Micro API tandem mass spectrometer (Waters, Manchester, UK).[@B22] Six calibrators and two control materials (mixture with 6-TGN and 6-MMP stock solutions and RBCs from pooled whole blood after removal of plasma and buffy coat) were used in each analysis. Within-run and between-run imprecision for thiopurine metabolites were below 10%. The limit of quantification was 5 ng/mL for 6-TGN and 50 ng/mL for 6-MMP.

Statistical methods
-------------------

All collected variables were subjected to descriptive analysis. Results are expressed as mean±standard deviation or range for numerical variables and as percentages for qualitative variables. A Student t-test or Mann-Whitney U test was used to compare numerical variables between groups and the χ^2^ test or Fisher exact test was used to investigate the relationship between the variables. A *p*-value \<0.05 was considered statistically significant.

RESULTS
=======

Baseline patient characteristics
--------------------------------

A total of 109 patients were studied. All patients were treated with AZA; the mean dose of AZA was 1.2±0.38 mg/kg/day. The demographic and clinical characteristics of patients enrolled in this study are shown in [Table 1](#T1){ref-type="table"}.

The mean 6-TGN concentration of the entire study population was 328.3±105.0 pmol/8×10^8^ RBC. The mean 6-TGN concentration was 299.7±77.1 pmol/8×10^8^ RBC in patients with active disease (n=24), and 336.3±110.7 pmol/8×10^8^ RBC among patients in remission (n=85). There were no statistical differences in 6-TGN levels between patients with active disease and patients in remission (*p*=0.73).

Frequency of ADR during AZA treatment
-------------------------------------

Definitions of ADR in this study are shown in [Table 2](#T2){ref-type="table"}. ADR occurred in 38 patients (34.8%). Among these patients, gastric intolerance occurred in two patients (1.8%), rash in two (1.8%), leukopenia in 24 (22.0%) and hair loss in 10 (9.2%) ([Table 2](#T2){ref-type="table"}). Only three of 24 leukopenia events could be explained by TPMT mutation. The mean AZA dose was 1.1±0.53 mg/kg/day in patients developing ADR, which was not significantly different from that (1.2±0.35 mg/kg/day) of the patients who did not develop ADR (*p*=0.45).

Patient characteristics with TPMT mutation
------------------------------------------

The distribution of the TPMT genotype was as follows: 102 patients had \*1/\*1 (wild type), one had \*3C/\*3C (homozygote, NM_000367.2: c.719A\>G; p.Tyr240Cys), four had \*1/\*3C, one had \*1/\*6, and one had \*1/\*16 (heterozygote). There were no statistical differences in initial AZA dose between the group of wild type TPMT and TPMT mutation. However, the 6-TGN concentration was 416.8±271.7 pmol/8×10^8^ RBC in patients with wild type TPMT and 1822.9±1493.9 pmol/8×10^8^ RBC in TPMT mutation (*p*=0.001). There were also statistical differences in white blood cell counts among two groups (*p*=0.028) ([Table 3](#T3){ref-type="table"}). The patient with \*3C/\*3C mutation required low dose of AZA, 0.18 mg/kg/day to maintain an optimal therapeutic range. Three of four patients with \*1/\*3C mutation had ADR such as leukopenia, rash and hair loss. However, two patients with \*1/\*6 and \*1/\*16 mutation did not present any ADR ([Table 4](#T4){ref-type="table"}).

Comparison of ADR, disease activity and AZA dose at pre- and post-thiopurine metabolite monitoring
--------------------------------------------------------------------------------------------------

Sixty-seven CD patients and 16 UC patients were selected for assessing ADR, disease activity (PCDAI or PUCAI) and AZA dose before and after thiopurine metabolite monitoring. ADR happened in 31 patients pre-metabolite monitoring and in only nine patients post-metabolite monitoring. AZA dose was 1.4±0.31 mg/kg/day before monitoring and 1.1±0.46 mg/kg/day after monitoring (*p*\<0.001). However, there were no statistical differences in disease activity during metabolite monitoring period (*p*=0.34) ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

Thiopurine has been commonly used for the maintenance of remission or for treating chronic active lesions in IBD. The use of AZA in adult patients with IBD has been well documented in the literature and also recently reported in pediatric studies.[@B23],[@B24],[@B25] Present, et al.[@B23] demonstrated that 67% of adult patients significantly decreased or terminated their steroid therapy 3-6 months after the introduction of oral immunomodulators. Similar results have been demonstrated in pediatric patients.[@B26],[@B27],[@B28]

One of the potentially severe side effects in AZA therapy is myelosuppression. AZA-induced bone marrow suppression has been attributed to the low enzyme activity caused by TPMT genetic polymorphism.[@B29],[@B30] Genetic polymorphism results in greater conversion of AZA to 6-TGN likely due to myelotoxicity.[@B3],[@B17] Consequently, the monitoring of 6-TGN levels has been known to be useful for managing IBD patients treating with AZA, since it may confirm the optimal AZA dose to maximize efficacy while minimizing the risk of side effect.[@B5],[@B31] The aim of this study was to investigate the influence of TPMT genotype and 6-TGN concentrations on the development of adverse effects during AZA treatment in children and adolescents with IBD.

TPMT can be examined for based on phenotype or genotype tests. TPMT genotyping is the method for detecting single nucleotide polymorphism responsible for TPMT inactivation. There is a good correlation between TPMT activity and genotyping.[@B32] The population can be divided into three groups founded on TPMT genetic polymorphism: wild type TPMT with high methylation activity (88%), heterozygosity with intermediate activity (11%) and homozygosity for deficient TPMT alleles with a low activity (0.3%).[@B33] Until now, 27 TPMT alleles which are \*2,\*3A,\*3B,\*3C,\*3D, and \*4 to \*25 responsible for possible deficient activity have been detected.[@B34]

In Asian populations, including Koreans, the frequencies of TPMT mutation are lower than those reported for Western countries.[@B35],[@B36],[@B37],[@B38],[@B39],[@B40] While the heterozygous \*2 or \*3A mutations are rare, \*3C mutation is most frequent and myelotoxicity develops more frequently in East Asia.[@B41],[@B42],[@B43],[@B44] The reason why Asian patients are troubled with bone marrow suppression during AZA administration is still unclear. One possible theory is the difference in TPMT genetic polymorphisms between Asian and Caucasian populations. Kim, et al.[@B45] from Korea suggested that it could be reasonable to obtain TPMT genotypes before starting AZA treatment for predicting the development of leukopenia.

A TPMT genotyping study of 400 Korean subjects suggested that TPMT \*1/\*1 (wild type) was 97.8% (391/400).[@B35] TPMT \*1/\*3C was found to be the most frequent polymorphism in the Korean population (1.8%). TPMT \*2, \*3A, and \*3B were not found in the study population. Two Korean subjects were genotyped as TPMT \*1/\*6 (0.5%). Another TPMT study of 147 Japanese IBD patients suggested that wild type for TPMT was 98.0% (144/147) and TPMT \*1/\*3C was 2.0% (3/147) similar to Korean study.[@B40] To our knowledge, our study is the first work to detect TPMT \*3C/\*3C and \*1/\*16 mutations and to evaluate 6-TGN concentrations and dosing of optimal AZA in Korean pediatric IBD patients. In our study, TPMT polymorphism was proven in seven patients. The patients with TPMT polymorphism required a low dose of AZA to attain an optimal therapeutic range of 6-TGN. TPMT \*3C/\*3C and \*1/\*3C mutation was highly associated with a risk of ADR as it is known. However, TPMT \*1/\*6 and \*1/\*16 mutations were not related with ADR. There is no doubt that TPMT testing is necessary before initiation of AZA to identify individuals who are homozygote recessive or have extremely low TPMT activity.[@B46] However, TPMT testing doesn\'t predict all cases of ADR such as leukopenia. Mutations of TPMT have been associated with leukopenia,[@B3],[@B13],[@B47],[@B48],[@B49] although other studies have reported that leukopenia is independent of TPMT polymorphisms.[@B50],[@B51],[@B52] Because only 3 of 24 leukopenia events could be explained by TPMT mutation, the association between TPMT polymorphisms and ADR was probably heterogeneous. However, we suggest that the correlation exists between TPMT polymorphism and the development of ADR because 4 of 7 patients with TPMT polymorphism presented ADR.

AZA is an inactive prodrug that is metabolized to produce the nucleotide metabolites, 6-TGN, 6-MMP, and 6-thiouracil. Among these metabolites, 6-TGN seems to be one of the active metabolites accountable for therapeutic efficacy. In diverse studies, significant correlations have been found between 6-TGN concentration and clinical response in IBD and a therapeutic range of 6-TGN concentration is 235-450 pmol/8×10^8^ RBC.[@B6],[@B53],[@B54],[@B55] A 6-TGN concentration of \>235 pmol/8×10^8^ RBC is associated with clinical response.[@B6],[@B53] The cutoff concentration above 450 pmol/8×10^8^ RBC is based on an increased risk of side effects (myelotoxicity[@B55] and nodular regenerative hyperplasia of the liver[@B56]) without an increase in efficacy. Patients with erythrocyte 6-MMP concentrations above 5700 pmol/8×10^8^ RBC are at increased risk of hepatotoxicity and are unlikely to respond to treatment by increasing the drug dose.[@B53],[@B57],[@B58] These patients are possibly preferentially metabolizing AZA through TPMT to form 6-MMP and may profit from reducing thiopurine dose by 50-75%, as well as careful monitoring of hematological parameters.[@B59]

Osterman, et al.[@B60] and Sandborn, et al.[@B61] documented that the doses of AZA in maintenance therapy to treat IBD were 2-3 mg/kg/day, and that 6-TGN concentrations above 235 pmol/8×10^8^ RBC were confirmed in most IBD patients with this dose. A study of Japanese children with IBD showed that similar 6-TGN concentrations should be targeted to maintain remission, although the amounts of AZA required to achieve the targeted 6-TGN concentration were lower than those used in Western countries.[@B62],[@B63] In Korea, lower doses of AZA (approximately 1.5-2 mg/kg AZA per day) are empirically used for the treatment of IBD patients.[@B64],[@B65] However, there has been no data on the dose of AZA that is needed to reach appropriate 6-TGN level in Korean children and adolescents with IBD.

In agreement with previous investigations,[@B5],[@B55],[@B60],[@B66] our study showed that the mean 6-TGN concentration was higher in patients with clinical remission (336.3±110.7 pmol/8×10^8^ RBC) than with active disease (299.7±77.1 pmol/8×10^8^ RBC). However, there were no statistical differences. In the present study, since thiopurine metabolite monitoring, ADR has markedly decreased and AZA dose reduced to 1.1±0.46 mg/kg/day with maintaining remission. Only 8 of 38 ADR events were associated with TPMT polymorphism; and the rest of the ADR events occurred in wild type of TPMT. Therefore, surveillance of ADR through thiopurine metabolite monitoring is possibly important to the patients, with not only TPMT polymorphism but also wild type of TPMT.

As we described above, our results indicated that 6-TGN concentration was higher than we expected in pediatric IBD patients, even though they were treated with low-dose of AZA. These results are similar to those of a study conducted in the Far East, however, different from studies reported in Western countries.[@B60],[@B61],[@B62],[@B66] One explanation for this might be an ethnic difference.

Our study had several limitations, including the small number of patients and the retrospective design. In Korea, the incidence and prevalence of IBD are still low compared with those in Western countries.[@B67] Considering these circumstances, we recruited not a few number of pediatric patients with IBD in Korea. Monitoring 6-TGN concentrations is helpful in developing a therapeutic strategy for pediatric and adolescent IBD patients. Although TPMT genotype and thiopurine metabolite monitoring could not completely explain the thiopurine-induced ADR, it could be helpful to examine TPMT genotypes before administering AZA and to measure 6-TGN concentrations during prescribing AZA in IBD patients. Clinicians should be cautious about the possibility of higher 6-TGN concentrations in Korean pediatric IBD patients, even if they are being treated with general AZA dose.
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Baseline Clinical Characteristics
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AZA, azathioprine; CD, Crohn\'s disease; UC, ulcerative colitis; PCDAI, pediatric CD activity index; PUCAI, pediatric UC activity index.
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Definitions and Frequencies of Adverse Drug Reactions (ADR) Encountered in the Study
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AZA, azathioprine; TPMT, thiopurine S-methyltransferase.
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Comparison of AZA Dose, 6-TGN Concentration and White Blood Cell Counts between the Group of Wild Type TPMT and TPMT Mutation
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AZA, azathioprine; WBC, white blood cell; 6-TGN, 6-thioguanine nucleotide; TPMT, thiopurine S-methyltransferase.
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Characteristics of Inflammatory Bowel Disease Patients with TPMT Mutation
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AZA, azathioprine; CD, Crohn\'s disease; UC, ulcerative colitis; WBC, white blood cell; 6-TGN, 6-thioguanine nucleotide; TPMT, thiopurin S-methyltransferase; ADR, adverse drug reactions; RBC, red blood cells.

6-methylmercaptopurine was below 5700 pmol/8×10^8^ RBC in all seven patients.
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Comparison of ADR, Disease Activity and AZA Dose at Pre- and Post-Thiopurine Metabolite Monitoring in 83 IBD Patients
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ADR, adverse drug reactions; AZA, azathioprine; IBD, inflammatory bowel disease.
